Ozempic
World news wrapup: 16 November 2023
Vengeance not sweet for censured Kiwi pharmacist; Belgian Ozempic weight loss ban; cheating allegations in UK pharmacy exam New Zealand: A pharmacist’s revenge against his former employers over theft accusations …
FDA approves new ‘King Kong’ weight loss drug
Potential blockbuster dubbed Zepbound to join cousin drug Mounjaro on US market Tirzepatide, Eli Lilly’s GIP and GLP-1 agonist, described by media as “the King Kong of drugs”, has been …
Ozempic fattens Commonwealth coffers – slightly
Ozempic manufacturer, Novo Nordisk’s tax bill more than doubled in the 2021/22 financial year, data from the Australian Taxation Office (ATO) reveals Surging demand for Novo Nordisk’s diabetes medication, Ozempic …
Dosing errors dominate Ozempic emergency calls
Over 200 calls in two years with a small number referred to hospital and low levels of intentional misuse Poisons information centres in Victoria and NSW have received over 200 …
The ‘Ozempic effect’ hits worldwide share market
Whether health industry or junk food business, steamroller popularity of weight loss drug shakes up stock prices The huge success of the new wave of GLP-1 (glucagon-like peptide-1) receptor agonist …
Fund weight loss drugs on PBS: MP
Coalition MP calls for extension of Pharmaceutical Benefits Scheme (PBS) listings of medications associated with weight loss to help tackle obesity Shadow Assistant Minister for Health, Aged Care and Indigenous …
Ozempic added to anti-doping watchlist
Athletes will be banned from using tramadol in-competition from 1 January 2024, with Ozempic (semaglutide) being added to the WADA “monitoring list” Use of diabetes treatment, Ozempic, by athletes is …
No new Ozempic scripts: TGA
Prescribers urged not to start new patients on Ozempic, as Novo Nordisk warns of supply shortages throughout 2024 Ozempic supplier, Novo Nordisk, is warning that supply of the diabetes medication …
Ozempic competitor to launch in spite of PBS knockback
Eli Lilly’s Mounjaro will be on the private scrip market by the end of September Revolutionary new type 2 diabetes drug Mounjaro – which is almost better known for producing …
Ozempic diabetes competitor gets PBS knockback
Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …
Regulator investigates Ozempic suicidal ideation link
Novo Nordisk’s diabetes medication, Ozempic (semaglutide) and weight-loss treatment Saxenda (liraglutide) are being investigated, following reports they may be associated with suicidal ideation The European Medicines Agency (EMA) is looking …
Ozempic shortage pain to continue until year’s end
TGA underscores ‘limited availability’ means drug should still only be prescribed for type-2 diabetes There will be continued “limited availability” of diabetes drug Ozempic until 31 December 2023 due to …